Menopausal HT for Women Living With HIV (HoT) (NCT06856174)
Menopausal Hormone Therapy for Women Living With HIV (HoT)
🩺 Plain-English Summary (8th-Grade Level)
Women living with HIV have been shown to experience more frequent and severe hot flashes and night sweats (collectively known as vasomotor symptoms) as compared to women living without HIV. This correlates with disturbed sleep, increased depressive symptoms, increased anxiety, worse mental function, interference with activities of daily living including work, and worse overall quality of life. Hormone therapy is considered to be the most effective therapy for hot flashes and night sweats and the most appropriate choice to prevent bone loss at the time of menopause for women without HIV. However, the usefulness of hormone therapy has not been specifically studied in women living with HIV. This trial is being done to see if: * There is evidence to support the use of hormone therapy (estradiol with or without progesterone) for the treatment of hot flashes and night sweats in women living with HIV * Hormone therapy improves mental function, mood, sleep, quality of life, bone health, heart health, and inflammation in women living with HIV * Hormone therapy is safe and tolerable for women living with HIV
Who can join: Review the eligibility criteria below.
Location: 31788 Alabama CRS — Birmingham, Alabama
Age range: 40 Years to 60 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (23 Sites)
- 31788 Alabama CRS — Birmingham, Alabama
- University of California, Los Angeles CARE Center CRS (601) — Los Angeles, California
- UCSD Antiviral Research Center CRS (701) — San Diego, California
- 801 University of California, San Francisco HIV/AIDS CRS — San Francisco, California
- Harbor - UCLA Med. Ctr. CRS — Torrance, California
- University of Colorado Hospital CRS (6101) — Aurora, Colorado
- The Ponce de Leon Center CRS (5802) — Atlanta, Georgia
- Northwestern University CRS (2701) — Chicago, Illinois
- 201 Johns Hopkins University CRS — Baltimore, Maryland
- 101 Massachusetts General Hospital (MGH) CRS — Boston, Massachusetts
- Brigham and Women's Hosp. ACTG CRS (107) — Boston, Massachusetts
- 2101 Washington University Therapeutics (WT) CRS — St Louis, Missouri
- New Jersey Medical School Clinical Research Center CRS (31786) — Newark, New Jersey
- Weill Cornell Chelsea CRS (7804) — New York, New York
- Columbia Physicians and Surgeons (P&S) CRS (30329) — New York, New York
- 3201 Chapel Hill CRS — Chapel Hill, North Carolina
- 3203 Greensboro CRS — Greensboro, North Carolina
- 2401 Cincinnati CRS — Cincinnati, Ohio
- Case CRS (2501) — Cleveland, Ohio
- Ohio State University CRS (2301) — Columbus, Ohio
- 6201 Penn Therapeutics CRS — Philadelphia, Pennsylvania
- Univ of Pittsburgh — Pittsburgh, Pennsylvania
- Houston AIDS Research Team CRS (31473) — Houston, Texas
📞 Contact the Study Coordinator
Phone: (301) 628-3348
Email: ACTGCT.gov@dlhcorp.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in HIV Infection
- Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant — La Jolla, California
- Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption — Birmingham, Alabama
- A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054) — Birmingham, Alabama
- Baricitinib Curative Repression of HIV-1 — Atlanta, Georgia
- Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated Strategy — Los Angeles, California
- Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study — La Jolla, California
Explore by condition: All HIV Infection clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.